Frequency of Allergic Reactions in Clinical Trials
Allergic reactions to icosapent ethyl (Vascepa), a purified EPA omega-3 fatty acid for cardiovascular risk reduction, occurred in less than 1% of patients in pivotal REDUCE-IT and ANCHOR trials. Hypersensitivity events, including rash, eczema, and pruritus, were reported at rates of 0.5-1.2% versus 0.4-0.9% on placebo.[1][2]
What Counts as an Allergic Reaction
Trials categorized hypersensitivity broadly: rash (2.1% vs 1.9% placebo), eczema (0.3% vs 0.2%), and rare anaphylaxis (<0.1%). Most were mild, with discontinuation rates under 0.5%. No increased anaphylaxis risk over placebo.[1][3]
Risk Factors and Patient Concerns
Patients with known fish/shellfish allergies face theoretical cross-reactivity due to marine sourcing, though purified icosapent ethyl minimizes this—post-marketing reports remain rare. FDA label advises caution; reactions may mimic common side effects like rash (1-3% overall).[2][4]
Comparison to Other Omega-3s
Unlike mixed EPA/DHA fish oils (e.g., Lovaza), icosapent ethyl shows lower hypersensitivity (1% vs 2-4% for fish oils), attributed to EPA purity and no DHA.[1][5] Generic omega-3 supplements report similar low rates but lack trial data.
Post-Marketing and Real-World Data
VAERS logs few severe allergies; incidence mirrors trials (<1%). No patents block generics yet—Vascepa exclusivity ends 2031, but formulation patents extend to 2039.[6][7]
[1]: REDUCE-IT trial (NEJM 2019) - https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[2]: Vascepa prescribing information - https://www.accessdata.fda.gov/drugsatfdadocs/label/2020/202057s020lbl.pdf
[3]: ANCHOR trial data - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.039159
[4]: DrugPatentWatch.com Vascepa patents - https://www.drugpatentwatch.com/p/tradename/VASCEPA
[5]: Lovaza label comparison - https://www.accessdata.fda.gov/drugsatfdadocs/label/2009/021657s016lbl.pdf
[6]: VAERS database query (icosapent ethyl) - https://vaers.hhs.gov/data.html
[7]: DrugPatentWatch.com exclusivity - https://www.drugpatentwatch.com/p/tradename/VASCEPA/patent-status